Clinical Trials Browser

Phase 4 × Completed × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01735955 2024-02-08

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

GastrointestinalLymphoidMyeloidOther hematologic neoplasmSarcoma

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Piebaldism, Gastrointestinal Stromal Tumors, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02546674 2022-07-22

NILOdeepR

Phase 4 Completed

171 enrolled 23 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00980018 2021-07-01

MACS0999

Phase 4 Completed

52 enrolled 14 charts

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01243489 2019-12-20

Crescendo

Phase 4 Completed

104 enrolled

MyeloidOther hematologic neoplasm

Patient Compliance, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01578213 2019-12-03

ISAV

Phase 4 Completed

112 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00171899 2017-02-23

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Phase 4 Completed

80 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00786812 2017-02-23

MACS0439

Phase 4 Completed

89 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01368523 2016-11-16

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

Phase 4 Completed

19 enrolled

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00845221 2016-10-11

Glivec in Pediatric Chronic Myeloid Leukemia (CML)

Phase 4 Completed

44 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01043874 2016-04-08

MACS0911

Phase 4 Completed

45 enrolled 9 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01227577 2016-02-08

MACS1428

Phase 4 Completed

128 enrolled 11 charts

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00081926 2009-11-23

Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Phase 4 Completed

112 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00390897 2008-11-27

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

Phase 4 Completed

360 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Clinical Trials

ROPEG

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

NILOdeepR

MACS0999

Crescendo

ISAV

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

MACS0439

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

Glivec in Pediatric Chronic Myeloid Leukemia (CML)

MACS0911

MACS1428

Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia